Amiodarone pills 200mg N30
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Description
Ingredients Amiodarone hydrochloride 200 mg Pharmacological action Antiarrhythmic agent class III, has antianginal effect. The antiarrhythmic effect is associated with the ability to increase the duration of the action potential of cardiomyocytes and the effective refractory period of the atria, ventricles of the heart, AV node, His bundle, Purkinje fibers. This is accompanied by a decrease in the automatism of the sinus node, a slowdown in AV conduction, a decrease in the excitability of cardiomyocytes. It is believed that the mechanism for increasing the duration of the action potential is associated with blockade of potassium channels (the excretion of potassium ions from cardiomyocytes is reduced). By blocking inactivated "fast" sodium channels, it has the effects characteristic of class I antiarrhythmic drugs. Slows down the slow (diastolic) depolarization of the cell membrane of the sinus node, causing bradycardia, inhibits AV-conduction (the effect of class IV antiarrhythmics). The antianginal effect is due to coronary dilating and anti-adrenergic effects, a decrease in myocardial oxygen demand. It has an inhibitory effect on the .- and & # 946. -Adrenoreceptors of the cardiovascular system (without their complete blockade). Reduces the sensitivity to hyperstimulation of the sympathetic nervous system, the tone of the coronary vessels. increases coronary blood flow. lowers heart rate. increases the energy reserves of the myocardium (by increasing the content of creatine sulfate, adenosine and glycogen). Reduces the OPSS and systemic blood pressure (with a / in the introduction). It is believed that amiodarone may increase the level of phospholipids in the tissues. Contains iodine. Affects the metabolism of thyroid hormones, inhibits the conversion of T3 to T4 (blocking thyroxin-5-deiodinase) and blocks the capture of these hormones by cardiocytes and hepatocytes, which leads to a weakening of the stimulating effect of thyroid hormones on the myocardium (T3 deficiency can lead to hyperproduction and thyrotoxicosis) . On ingestion, the onset of action is from 2-3 days to 2-3 months, the duration of action is also variable - from several weeks to several months. After intravenous administration, the maximum effect is achieved in 1-30 minutes and lasts for 1-3 hours.
Dosage and administration
When administered orally for adults, the initial single dose is 200 mg. For children, the dose is 2.5-10 mg / day.The scheme and duration of treatment set individually. For on / in the introduction (jet or drip) single dose of 5 mg / kg daily dose - up to 1.2 g (15 mg / kg). Precautions During the period of treatment may worsen psoriasis. With pheochromocytoma, propranolol can be used only after taking an alpha blocker. After a long course of treatment, propranolol should be discontinued gradually, under the supervision of a physician. Against the background of treatment with propranolol, IV administration of verapamil, diltiazem should be avoided. A few days before anesthesia, you must stop taking propranolol or pick up a remedy for anesthesia with minimal negative inotropic effects. Influence on the ability to drive vehicles and control mechanisms In patients whose activities require increased attention, the question of the use of propranolol on an outpatient basis should be addressed only after evaluating the individual response of the patient. Side effect From the side of the cardiovascular system: sinus bradycardia (refractory to m-cholinoblockers), AV-blockade, with prolonged use - progression of CHF, ventricular arrhythmia of the "pirouette" type, enhancement of the existing arrhythmia or its occurrence, with parenteral use - reduction of blood pressure . On the part of the endocrine system: the development of hypo-or hyperthyroidism. On the part of the respiratory system: with prolonged use - cough, shortness of breath, interstitial pneumonia or alveolitis, pulmonary fibrosis, pleurisy, with parenteral administration - bronchospasm, apnea (in patients with severe respiratory failure). On the part of the digestive system: nausea, vomiting, loss of appetite, dulling or loss of taste, a feeling of heaviness in the epigastrium, abdominal pain, constipation, flatulence, diarrhea. rarely - increased activity of hepatic transaminases, with long-term use - toxic hepatitis, cholestasis, jaundice, cirrhosis of the liver. Nervous system disorders: headache, weakness, dizziness, depression, fatigue, paresthesia, auditory hallucinations, with prolonged use - peripheral neuropathy, tremor, memory impairment, sleep, extrapyramidal manifestations, ataxia, optic neuritis, with parenteral administration - intracranial hypertension.On the part of the senses: uveitis, lipofuscin deposition in the corneal epithelium (if the deposits are significant and partially fill the pupil - complaints about luminous points or a veil in front of the eyes in bright light), retina microslegation. From the hematopoietic system: thrombocytopenia, hemolytic and aplastic anemia. Dermatological reactions: skin rash, exfoliative dermatitis, photosensitivity, alopecia. rarely - gray-blue staining of the skin. Local reactions: thrombophlebitis. Other: epididymitis, myopathy, reduced potency, vasculitis, with parenteral administration - fever, increased sweating. Special instructions C should be used with caution in chronic heart failure, liver failure, bronchial asthma, in elderly patients (high risk of developing severe bradycardia), under the age of 18 years (efficacy and safety have not been established). Should not be used in patients with severe respiratory failure. Before starting the use of amiodarone, an x-ray examination of the lungs and thyroid function should be carried out, and, if necessary, correction of electrolyte disorders. With long-term treatment requires regular monitoring of thyroid function, consultation of an ophthalmologist and x-ray examination of the lungs. Parenteral can be used only in specialized departments of hospitals under the constant control of blood pressure, heart rate and ECG. Patients receiving amiodarone should avoid direct exposure to sunlight. With the abolition of amiodarone possible recurrence of cardiac arrhythmias. May affect the results of the test of accumulation of radioactive iodine in the thyroid gland. Amiodarone should not be used simultaneously with quinidine, beta-blockers, calcium channel blockers, digoxin, coumarin, doxepin. Use during pregnancy and lactation. Use during pregnancy and lactation is contraindicated. Amiodarone and desmethylamiodarone penetrate the placental barrier, their concentrations in the fetal blood are 10% and 25%, respectively, of the concentration in the mother’s blood. Amiodarone and desmethylamiodarone are excreted in breast milk.Type: Drug Quantity in package, pcs: 30 Shelf life: 24 months Scope of application: Cardiovascular diseases Active ingredient: Amiodarone (Amiodarone) Route of administration: Oral Vacation schedule: Prescription Release form: Prescription Storage conditions: In a dry place , In a dark place, Keep out of children Maximum storage temperature, ° С: 25 Pharmacological group: C01BD01 Amiodarone Minimum age: 18 yearsActive ingredients
Amiodarone
Release form
Pills
Composition
Amiodarone hydrochloride 200 mg
Pharmacological effect
Antiarrhythmic agent class III, has antianginal effect. The antiarrhythmic effect is associated with the ability to increase the duration of the action potential of cardiomyocytes and the effective refractory period of the atria, ventricles of the heart, AV node, His bundle, Purkinje fibers. This is accompanied by a decrease in the automatism of the sinus node, a slowdown in AV conduction, a decrease in the excitability of cardiomyocytes. It is believed that the mechanism for increasing the duration of the action potential is associated with blockade of potassium channels (the excretion of potassium ions from cardiomyocytes is reduced). By blocking inactivated "fast" sodium channels, it has the effects characteristic of class I antiarrhythmic drugs. Slows down the slow (diastolic) depolarization of the cell membrane of the sinus node, causing bradycardia, inhibits AV-conduction (the effect of class IV antiarrhythmics). The antianginal effect is due to coronary dilating and anti-adrenergic effects, a decrease in myocardial oxygen demand. It has an inhibiting effect on & # 945 .- and & # 946. -Adrenoreceptors of the cardiovascular system (without their complete blockade). Reduces the sensitivity to hyperstimulation of the sympathetic nervous system, the tone of the coronary vessels. increases coronary blood flow. lowers heart rate. increases the energy reserves of the myocardium (by increasing the content of creatine sulfate, adenosine and glycogen). Reduces the OPSS and systemic blood pressure (with a / in the introduction). It is believed that amiodarone may increase the level of phospholipids in the tissues. Contains iodine. Affects the metabolism of thyroid hormones, inhibits the conversion of T3 to T4 (blocking thyroxin-5-deiodinase) and blocks the capture of these hormones by cardiocytes and hepatocytes, which leads to a weakening of the stimulating effect of thyroid hormones on the myocardium (T3 deficiency can lead to hyperproduction and thyrotoxicosis) .On ingestion, the onset of action is from 2-3 days to 2-3 months, the duration of action is also variable - from several weeks to several months. After the on / in the introduction of the maximum effect is achieved in 1-30 minutes and lasts 1-3 hours.
Indications
Treatment and prevention of paroxysmal arrhythmias: life-threatening ventricular arrhythmias (including ventricular tachycardia), prevention of ventricular fibrillation (including after cardioversion), supraventricular arrhythmias (usually with the ineffectiveness or impossibility of another therapy, especially associated with WPW syndrome, incl. paroxysm of atrial fibrillation and flutter. atrial and ventricular premature beats. arrhythmias on the background of coronary insufficiency or chronic heart failure, parasystole, ventricular arrhythmias in patients with Chagas myocarditis. angina pectoris
Contraindications
Sinus bradycardia, SSSU, sinoatrial blockade, AV-blockade II-III degree (without the use of a pacemaker), cardiogenic shock, hypokalemia, collapse, arterial hypotension, hypothyroidism, thyrotoxicosis, interstitial lung disease, administration of MAO inhibitors, pregnancy, lactation period, an environment. to amiodarone and iodine.
Use during pregnancy and lactation
Use in pregnancy and lactation is contraindicated. Amiodarone and desmethylamiodarone penetrate the placental barrier, their concentrations in the fetal blood are 10% and 25%, respectively, of the concentration in the mother’s blood. Amiodarone and desmethylamiodarone are excreted in breast milk.
Dosage and administration
When ingested for adults, the initial single dose is 200 mg. For children, the dose is 2.5-10 mg / day. The scheme and duration of treatment set individually. For on / in the introduction (jet or drip) single dose of 5 mg / kg daily dose - up to 1.2 g (15 mg / kg).
Side effects
On the part of the cardiovascular system: sinus bradycardia (refractory to m-holinoblokatorami), AV-blockade, with prolonged use - the progression of CHF, ventricular arrhythmia type "pirouette", strengthening of the existing arrhythmia or its occurrence, with parenteral use - lowering blood pressure. On the part of the endocrine system: the development of hypo-or hyperthyroidism.On the part of the respiratory system: with prolonged use - cough, shortness of breath, interstitial pneumonia or alveolitis, pulmonary fibrosis, pleurisy, with parenteral administration - bronchospasm, apnea (in patients with severe respiratory failure). On the part of the digestive system: nausea, vomiting, loss of appetite, dulling or loss of taste, a feeling of heaviness in the epigastrium, abdominal pain, constipation, flatulence, diarrhea. rarely - increased activity of hepatic transaminases, with long-term use - toxic hepatitis, cholestasis, jaundice, cirrhosis of the liver. Nervous system disorders: headache, weakness, dizziness, depression, fatigue, paresthesia, auditory hallucinations, with prolonged use - peripheral neuropathy, tremor, memory impairment, sleep, extrapyramidal manifestations, ataxia, optic neuritis, with parenteral administration - intracranial hypertension. On the part of the senses: uveitis, lipofuscin deposition in the corneal epithelium (if the deposits are significant and partially fill the pupil - complaints about luminous points or a veil in front of the eyes in bright light), retina microslegation. From the hematopoietic system: thrombocytopenia, hemolytic and aplastic anemia. Dermatological reactions: skin rash, exfoliative dermatitis, photosensitivity, alopecia. rarely - gray-blue staining of the skin. Local reactions: thrombophlebitis. Other: epididymitis, myopathy, reduced potency, vasculitis, with parenteral administration - fever, increased sweating.
special instructions
On the part of the cardiovascular system: sinus bradycardia (refractory to m-holinoblokatorami), AV-blockade, with prolonged use - the progression of CHF, ventricular arrhythmia type "pirouette", strengthening of the existing arrhythmia or its occurrence, with parenteral use - lowering blood pressure. On the part of the endocrine system: the development of hypo-or hyperthyroidism. On the part of the respiratory system: with prolonged use - cough, shortness of breath, interstitial pneumonia or alveolitis, pulmonary fibrosis, pleurisy, with parenteral administration - bronchospasm, apnea (in patients with severe respiratory failure). On the part of the digestive system: nausea, vomiting, loss of appetite, dulling or loss of taste, a feeling of heaviness in the epigastrium, abdominal pain, constipation, flatulence, diarrhea. rarely - increased activity of hepatic transaminases, with long-term use - toxic hepatitis, cholestasis, jaundice, cirrhosis of the liver.Nervous system disorders: headache, weakness, dizziness, depression, fatigue, paresthesia, auditory hallucinations, with prolonged use - peripheral neuropathy, tremor, memory impairment, sleep, extrapyramidal manifestations, ataxia, optic neuritis, with parenteral administration - intracranial hypertension. On the part of the senses: uveitis, lipofuscin deposition in the corneal epithelium (if the deposits are significant and partially fill the pupil - complaints about luminous points or a veil in front of the eyes in bright light), retina microslegation. From the hematopoietic system: thrombocytopenia, hemolytic and aplastic anemia. Dermatological reactions: skin rash, exfoliative dermatitis, photosensitivity, alopecia. rarely - gray-blue staining of the skin. Local reactions: thrombophlebitis. Other: epididymitis, myopathy, reduced potency, vasculitis, with parenteral administration - fever, increased sweating.